Early OCTA Changes of Type 3 Macular Neovascularization Following Brolucizumab Intravitreal Injections

Background and Objectives: Brolucizumab is a novel anti-vascular endothelial growth factor (VEGF), whose efficacy has been shown in the Hawk and Harrier phase 3 clinical studies. The goal of the present case series is to report initial results of brolucizumab intravitreal injections (IVI) on type 3...

Full description

Bibliographic Details

Main Authors:	Anthony Gigon, Maria Vadalà, Vincenza M. E. Bonfiglio, Michele Reibaldi, Chiara M. Eandi
Format:	Artigo
Language:	Inglês
Published:	MDPI AG 2022-08-01
Series:	Medicina
Subjects:	neovascular age-related macular degeneration type 3 neovascularization retinal angiomatous proliferation brolucizumab optical coherence tomography angiography intravitreal injection
Online Access:	https://www.mdpi.com/1648-9144/58/9/1180
Tags:	Add Tag No Tags, Be the first to tag this record!